7 results
Comparison of oral anticoagulant agents (DOACS + Warfarin)

Reference: ENLS 2017 Pharmacotherapy. Neurocritical Care Journal.

#DOAC #Dosing #Oral
Comparison of oral ... anticoagulant agents ... (DOACS + Warfarin ... #DOAC #Dosing #Oral ... #Table #Pharmacology
Key Characteristics of Old and New Potassium-Binding Agents

- Dr. Edgar V. Lerma https://twitter.com/edgarvlermamd

#Potassium #Binding #KBinders #Kayexelate
Potassium-Binding Agents ... Potassium #Binding #KBinders ... #Kayexelate #Comparison ... #Table #Pharmacology ... HyperKalemia #Nephrology #Agents
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
anti-hyperglycemic agents ... anti-hyperglycemic agents ... available to manage Type ... anti-hyperglycemic agents ... pharmacotherapy #table
Cardiac Valve Replacement - Anticoagulation INR Targets and Antiplatelet by Valve Type

Bioprosthetic valves require at least
Antiplatelet by Valve Type ... anticoagulants (DOACs ... valves since these agents ... #INR #Target #DOAC ... #Table #Replacement
Table 22 provides the characteristics of various phosphate-binding agents.
#Pharmacology #Nephrology #Phosphate #Phosphorus #Binders #Comparison #Table #Disadvantages
Table 22 provides ... phosphate-binding agents ... Phosphate #Phosphorus #Binders ... #Comparison #Table
Potassium-Binding Agents to Treat Hyperkalemia
Sodium zirconium cyclosilicate (Lokelma):
 • Mechanism: Preferentially captures K in exchange for
Potassium-Binding Agents ... calcium for K; also binds ... nonspecifically binds ... #pharmacology #table ... #comparison #binders
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
- Any adverse events ... , follow ACC algorithm ... Risk Stratify Type ... What is the type ... postoperative cardiac events